Rousselot Secures Brazilian Patent for Advanced Softgel Capsule Technology Stabicaps™

This latest patent, adding to those already granted by the European Patent Office (EPO) in 2022 and the U.S. Patent and Trademark Office (USPTO) in 2023, strengthens Rousselot’s intellectual property (IP) portfolio and highlights its commitment to innovation in gelatin-based delivery systems.

StabiCaps is designed to improve the stability and release profile of softgel capsules. By reducing crosslinking, a common challenge in capsule formulations, StabiCaps enhances the release of active compounds, enabling nutraceutical producers to meet rising consumer demand for reliable and bioavailable softgel supplements. With the global softgel market projected to grow at a 6.3% CAGR over the next four years(2), StabiCaps is well-positioned as a valuable solution in this expanding sector.

“StabiCaps technology offers significant advantages in stability and efficacy for nutraceutical producers, along with the attractive, natural appeal of gelatin,” said Pierre-Albert Thomas, Rousselot Functional Ingredients Director. “Securing three major international patents, including this latest one in Brazil, underscores the unique value of our technology. We are excited to see how this recognition will open up new opportunities for dietary supplement producers in the rapidly evolving Brazilian health and wellness market.”

Learn more about the benefits of StabiCaps and explore the rest of Rousselot’s world-class gelatin solutions portfolio at www.rousselot.com.